Review Article
PPAR Ligands for Cancer Chemoprevention
Table 3
Clinical trials on the anticancer effects of PPARγ ligands.
| Clinical trials | Drug | Results | Reference no. |
| Patients with intermediate to high-grade liposarcomas (case reports) | Troglitazone | Histlogical and biochemical differentiation | [90] | Phase II study on patients with histologically-confirmed
prostate cancer and no symptomatic metastatic disease | Troglitazone | Lengthened stabilization of prostate-specific antigen | [91] | 75-year-old patient with an occult recurrent prostate cancer (case reports) | Troglitazone | Reduced prostate-specific antigen | [92] | Phase II study on patients with metastatic colon cancer | Troglitazone | No significant effect | [93] | Phase II study on patients with liposarcoma | Rosiglitazone | Lengthened mean time of progression | [94] | Phase II study on patients with refractory breast cancer | Troglitazone | No significant effect | [95] | Phase II study on patients with thyroglobulin-positive and radioiodine-negative differentiated
thyroid cancer | Rosiglitazone | Induced radioiodine
uptake | [96] | Phase I study on patients with solid tumors | LY293111 | The recommended oral dose (600 mg/day) for phase II trial | [97] |
|
|